Biogen
Idec BIIB today announced results from several new
analyses of TYSABRI® (natalizumab) data that demonstrate its
effectiveness in reducing multiple sclerosis (MS) disease activity. This
effect was particularly significant in people with relapsing MS who
initiated treatment when they had lower Expanded Disability Status Scale
(EDSS) scores as well as in those who have been treated for more than
two years. These data will be presented at the 29th Congress
of the European Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS) in Copenhagen, Denmark from 2-5 October.
“These analyses build upon a growing body of evidence that demonstrates
greater clinical benefits for people with MS when TYSABRI is initiated
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in